retatrutide phase 2 nejm 2023 obesity trial jastreboff ๐ may be redefining treatment. New data from TRIUMPH-1 showed: ๐ฅ ~28% average weight loss over 80 weeks ๐ฅ >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Retatrutide Meets Weight Loss Endpoints
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Oct 8 - Oct 13





















/assets/images/provider/photos/2775923.jpeg)








